These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34046513)

  • 21. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
    Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
    J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral Adherence, Elevated Viral Load, and Drug Resistance Mutations in Human Immunodeficiency Virus-infected Women Initiating Treatment in Pregnancy: A Nested Case-control Study.
    Myer L; Redd AD; Mukonda E; Lynch BA; Phillips TK; Eisenberg A; Hsiao NY; Capoferri A; Zerbe A; Clarke W; Lesosky M; Breaud A; McIntyre J; Bruno D; Martens C; Abrams EJ; Reynolds SJ
    Clin Infect Dis; 2020 Jan; 70(3):501-508. PubMed ID: 30877752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of effectiveness of adherence counselling in reversing virological failure among patients on long-term antiretroviral therapy in rural Uganda.
    Birungi J; Cui Z; Okoboi S; Kapaata A; Munderi P; Mukajjanga C; Nanfuka M; Nyonyintono MS; Kim J; Zhu J; Kaleebu P; Moore DM
    HIV Med; 2020 Jan; 21(1):21-29. PubMed ID: 31432614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
    Eholie SP; Moh R; Benalycherif A; Gabillard D; Ello F; Messou E; Zoungrana J; Diallo I; Diallo M; Bado G; Cisse M; Maiga AI; Anzian A; Toni TD; Congo-Ouedraogo M; Toure-Kane C; Seydi M; Minta DK; Sawadogo A; Sangaré L; Drabo J; Karcher S; Le Carrou J; de Monteynard LA; Peytavin G; Gabassi A; Girard PM; Chaix ML; Anglaret X; Landman R;
    Lancet HIV; 2019 Nov; 6(11):e750-e759. PubMed ID: 31601544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
    Boender TS; Hamers RL; Ondoa P; Wellington M; Chimbetete C; Siwale M; Labib Maksimos EE; Balinda SN; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Stevens W; Rinke de Wit TF; Sigaloff KC
    J Infect Dis; 2016 Sep; 214(6):873-83. PubMed ID: 27402780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
    Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Change in Viral Load Count and Its Predictors Among Unsuppressed Viral Load Patients Receiving an Enhanced Adherence Counseling Intervention at Three Hospitals in Northern Ethiopia: An Exploratory Retrospective Follow-Up Study.
    Diress G; Linger M
    HIV AIDS (Auckl); 2020; 12():869-877. PubMed ID: 33324112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
    Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
    Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in CD4 and viral load testing 2005 to 2018: multi-cohort study of people living with HIV in Southern Africa.
    Zaniewski E; Dao Ostinelli CH; Chammartin F; Maxwell N; Davies MA; Euvrard J; van Dijk J; Bosomprah S; Phiri S; Tanser F; Sipambo N; Muhairwe J; Fatti G; Prozesky H; Wood R; Ford N; Fox MP; Egger M
    J Int AIDS Soc; 2020 Jul; 23(7):e25546. PubMed ID: 32640106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
    Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A
    AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa.
    Guichet E; Aghokeng A; Serrano L; Bado G; Toure-Kane C; Eymard-Duvernay S; Villabona-Arenas CJ; Delaporte E; Ciaffi L; Peeters M
    AIDS Res Hum Retroviruses; 2016 Dec; 32(12):1159-1162. PubMed ID: 27342228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
    Thompson JA; Kityo C; Dunn D; Hoppe A; Ndashimye E; Hakim J; Kambugu A; van Oosterhout JJ; Arribas J; Mugyenyi P; Walker AS; Paton NI;
    Clin Infect Dis; 2019 Mar; 68(7):1184-1192. PubMed ID: 30060027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
    Teasdale CA; Sogaula N; Yuengling KA; Wang C; Mutiti A; Arpadi S; Nxele M; Pepeta L; Mogashoa M; Rivadeneira ED; Abrams EJ
    J Int AIDS Soc; 2018 Aug; 21(8):e25168. PubMed ID: 30094952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mobile Text Messaging to Improve Medication Adherence and Viral Load in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A Repeated Measures Study.
    King E; Kinvig K; Steif J; Qiu AQ; Maan EJ; Albert AY; Pick N; Alimenti A; Kestler MH; Money DM; Lester RT; Murray MCM
    J Med Internet Res; 2017 Jun; 19(6):e190. PubMed ID: 28572079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanded access to viral load testing and use of second line regimens in Haiti: time trends from 2010-2017.
    Wang Y; Barnhart S; Francois K; Robin E; Kalou M; Perrin G; Hall L; Koama JB; Marinho E; Balan JG; Honoré JG; Puttkammer N
    BMC Infect Dis; 2020 Apr; 20(1):283. PubMed ID: 32299389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.
    Salou M; Dagnra AY; Butel C; Vidal N; Serrano L; Takassi E; Konou AA; Houndenou S; Dapam N; Singo-Tokofaï A; Pitche P; Atakouma Y; Prince-David M; Delaporte E; Peeters M
    J Int AIDS Soc; 2016; 19(1):20683. PubMed ID: 27125320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
    Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
    AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.
    Bachmann N; von Braun A; Labhardt ND; Kadelka C; Günthard HF; Sekaggya-Wiltshire C; Castelnuovo B; Kambugu A; Lejone TI; Böni J; Yerly S; Perreau M; Klimkait T; Kouyos RD; Fehr J;
    J Antimicrob Chemother; 2019 Feb; 74(2):468-472. PubMed ID: 30476115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.